Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 8/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 7/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845943 | 1.00 | ADRA1D (0.44) | ADRA1DADRA1AADRA1BGAARAB9A | |
| SCHEMBL7286936 | 0.83 | LMNA (0.50) | GAARAB9ASMN1; SMN2TSHR | |
| SCHEMBL6631842 | 0.82 | KMT2A (0.38) | GAARAB9ASMN1; SMN2L3MBTL1PKM | |
| SCHEMBL7199693 | 0.80 | MTNR1A (0.50) | GAASMN1; SMN2 | |
| SCHEMBL7215975 | 0.79 | HTR1A (0.60) | HTR1ASLC6A4 | |
| SCHEMBL6105410 | 0.77 | HSP90AA1 (0.35) | GAARAB9ASMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL4335129 | 0.77 | NR3C1 (0.37) | GAARAB9ASMN1; SMN2L3MBTL1HTR1A | |
| SCHEMBL6107714 | 0.77 | HTR1A (0.39) | HTR1ASLC6A4TSHR | |
| SCHEMBL5767727 | 0.77 | CA2 (0.36) | GAARAB9ASMN1; SMN2TSHR | |
| SCHEMBL5768634 | 0.77 | CA2 (0.36) | GAASMN1; SMN2HTR1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041683-B2 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1, 4-benzodiozan | WYETH (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1381600-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | Wyeth, A Corporation of the State of Delaware (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030236241-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH | 2003-12-25 | — | — | US | disclosed |
| US-6559169-B2 | For therapy of depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder attention deficit disorder,obsessive compulsive disorder, obesity, eating disorders, sexual dysfunction | WYETH | 2003-05-06 | — | — | US | disclosed |
| US-20020193400-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002085896-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-BENZODIOXAN | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193400-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | OPRD1, DRD1, DRD2 | ADRA1D 22/4885ADRA1A 103/4885ADRA1B 110/4885 |
| US-20030236241-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | OPRD1, DRD1, DRD2 | ADRA1D 22/4885ADRA1A 103/4885ADRA1B 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.